Introduction
Genomic ampli®cation is a common mechanism leading to deregulated gene expression in human cancers. In neuroblastoma, N-myc ampli®cation has been found to correlate with aggressive tumor growth and can serve as a predictor of clinical outcome (Schwab and Amler, 1990) . There is evidence that ampli®cation rather than up-regulation of basal expression is the main mechanism for the loss of auto-regulation of N-myc (Sivak et al., 1997) and for its over-expression (De Bernardi et al., 1995; Lutz and Schwab, 1997) . However, it is not clear how N-myc ampli®cation results in poor outcome (Hiyama et al., 1991; Nisen et al., 1988; Slavc et al., 1990) . It is possible that the co-ampli®cation of other DNA sequences may contribute to heterogeneity in the neuroblastoma phenotype.
The process of gene ampli®cation usually involves co-ampli®cation of extensive regions of DNA that share a common origin. The N-myc gene spans approximately 7 kb, whereas the size of the N-myc amplicon varies between 350 kb to over 1 Mb (Akiyama et al., 1994; Hiemstra et al., 1994; Kanda et al., 1983) . Co-ampli®cation of other¯anking genes, that may in¯uence disease progression, has been suggested (George et al., 1996; Squire et al., 1995) . Several candidate genes localized in the vicinity of the N-myc locus on 2p23-24 have been investigated. They have included ornithine decarboxylase (ODC) (Tonin et al., 1989) , ribonucleotide reductase (RRM2), the matrix receptor gene syndecan-1 (George et al., 1996) , and the DEAD-box gene DDX1 (George et al., 1996; Squire et al., 1995) . Only the DDX1 gene has been shown to be frequently co-ampli®ed with N-myc in neuroblastoma. The co-ampli®cation of sequences homologous to a hamster ODC c-DNA has been described for a single tumor (Tonin et al., 1989) , but more recent studies (George et al., 1996) failed to show co-ampli®cation of ODC with N-myc in neuroblastoma.
We have implemented an approach for the twodimensional (2-D) separation of human genomic restriction fragments to detect novel genomic alterations in neuroblastoma cell lines and primary tumors (Thoraval et al., 1996a; Wimmer et al., 1997) . The 2-D approach allows the identi®cation and isolation of as yet unknown ampli®ed sequences. The use of the enzyme NotI to digest DNA and the tagging of the fragments at the NotI ends allows preferential visualization and quantitative analysis of fragments containing CpG islands. We report the identi®cation and cloning of a novel CpG island that is frequently co-ampli®ed with the N-myc gene in neuroblastoma. We have cloned and characterized the gene associated with the CpG island, which we have designated NAG (neuroblastoma ampli®ed gene). We show that ampli®cation of this gene is correlated with over-expression. Ampli®cation of NAG was observed in 63% of neuroblastoma cell lines and 70% of neuroblastoma tumors with N-myc gene ampli®cation.
Results
Cloning of two NotI/DpnII fragments that are co-ampli®ed in neuroblastoma cell lines An initial analysis was undertaken in which genomic DNA from six neuroblastoma cell lines was digested with NotI/EcoRV for the ®rst-dimension separation and in situ with DpnII for the second-dimension separation. Four of the six cell lines contained an ampli®ed N-myc gene, as determined by Southern analysis. The 2-D patterns obtained for the six cell lines were compared to a large series of more than 200 patterns of a variety of normal tissues and other malignant and non-malignant cell lines. The patterns of neuroblastoma cell lines included several multi-copy DNA fragments observed in most other patterns and attributed to repetitive DNA elements in the genome (Kuick et al., 1996) (Figure 1) . Some of the other multi-copy fragments that are visible in the 2-D patterns of the neuroblastoma cell lines have previously been shown to be derived from repetitive DNA sequences that get demethylated in neuroblastoma and other tumors (NBL fragments) (Figure 1 ) (Thoraval et al., 1996b) . Two multi-copy fragments, designated NBA-2A and NBA-2B were both present in three cell lines with N-myc gene ampli®cation (IMR-32, STA-NB4 and STA-NB11). These two fragments occurred in the other three cell lines (NGP-127, SKNSH and Sy5y) as well as in non-neuroblastoma cell lines, at an intensity level corresponding approximately to two copies in the genome (Figure 1 ). The two fragments were not derived from the N-myc gene since the latter yields, with the enzyme combination utilized, fragments of 410 Kb that are outside the ®rst-dimension separation range.
The two fragments were cloned from preparative 2-D gels as described in Materials and methods. The fragments were sequenced, and the novel sequences were compared with known sequences from the EMBL database. Starting at their NotI sites, the 139 bp fragment NBA-2A and the 455 bp fragment NBA-2B contained sequence stretches of 39 bp and 182 bp, respectively, that were identical with a CpG island in the database. Thus, the two fragments contained (one at its 5' end and the other at its 3' end) the same NotI restriction site. An EST search yielded a match between a 54 bp stretch in NBA-2B and the 5' sequence of fetal heart cDNA clone K6533. The identity between the two sequences stopped at an exon-intron boundary consensus sequence in NBA-2B.
Cloning of the NAG gene
The fetal heart cDNA clone contained a 2085 bp that was sequenced in its entirety. A 750 bp stretch at the 3' end of this sequence matched several ESTs from Homo sapiens. These sequences formed two tentative human consensuses (THC) in a TIGR-THC sequence search. Three of the cDNA clones also had 5' sequences in the EST database. However, the 5' sequences of these three clones had no homology with the fetal heart cDNA clone sequence. RT ± PCR, performed with primers that targeted a 1137 bp region in the middle of the fetal cDNA clone sequence ampli®ed a 3.56 kb fragment from two neuroblastoma cell lines that contained the ampli®ed NBA-2A and -2B fragments, instead of the expected 1137 bp fragment. Similar RT ± Figure 1 Digital image of DNA-fragments of a neuroblastoma cell line STA-NB-11 (left) and peripheral blood lymphocytes of the patient from whose tumor tissue the cell line originated (right). Whole genomic DNA digested with the enzymes NotI and EcoRV and DpnII is separated on a polyacrylamide gel. Large arrows point to genomic fragments that appear frequently increased in intensity in neuroblastoma tissues and cell lines due to gene ampli®cation. Fragments NBA-2A and NBA-2B were target cloned from the gel of the neuroblastoma cell line. Small arrows indicate repetitive fragments that are frequently demethylated in neuroblastoma described elsewhere (Thoraval et al., 1996a,b) PCR results were obtained with normal fetal tissues, namely adrenal, brain, and pancreas (data not shown). Sequence analysis of this 3567 bp cDNA fragment revealed a loss of 2430 bp between base 1316 to 1317 in the fetal heart cDNA sequence. A 4510 bp NAG cDNA sequence (Accession #AF056195) was, therefore, deduced from the sequence of overlapping clones. A Northern blot with the fetal heart cDNA probe con®rmed the presence of a single band of estimated 4.5 kb in two neuroblastoma cell lines that contained ampli®ed NBA-2A and -2B fragments (data not shown).
The 4510 kb NAG cDNA sequence contains an open reading frame (ORF) starting with ATG at base 352. This site ®ts well the consensus sequence for a translation initiation site (Kozak, 1987) . The ORF translate encodes a predicted protein of 1352 amino acid residues. A polyadenylation signal is located at the 3' end 14 bp upstream from a poly-A stretch. A BLAST search did not reveal identity between NAG and any known gene. However, homology analysis with the predicted amino acid sequence of NAG revealed two regions, from aa 2 ± 290 and aa 619 ± 816, that showed 22% (66/213) and 26% (57/213) identical residues to a 1576 aa C. elegans protein of unknown function. A protein domain search uncovered a leucine zipper domain at 1211 aa and a ribosomal protein S14 signature domain at 1172 aa for the predicted protein sequence of NAG.
The NBA-2A and -2B fragments contain part of the promoter and 53 bp of the ®rst exon and part of the ®rst intron of NAG. It is likely that the CpG island that is encompassed by fragments NBA-2A and -2B extends further into the ®rst intron beyond the 3' sequence of NBA-2A.
NAG maps to the N-myc locus on chromosome 2p23-24
We performed double color FISH analysis to map NAG in relation to the N-myc gene. A 1.3 kb fragment that contained the cloned NotI/DpnII fragment NBA-2A was isolated from a genomic NotI/EcoRV library. This fragment was labeled with biotin and used together with a digoxygenin-labeled N-myc probe to hybridize BrdU-treated normal human metaphase chromosomes. Twenty-one metaphase spreads were analysed. Seventy-six percent of the hybridization signals of the novel gene were found distal to the Nmyc gene; 17% of the hybridization signals were found at the same position; and only 7% of the FISH signals were located proximal. In one metaphase chromosome, the signals were found proximal and distal (Figure 2) . The location of the novel gene in close vicinity to Nmyc gene and its exclusive ampli®cation with N-myc indicate that N-myc and the novel gene are coampli®ed within the same amplicon.
NAG is frequently co-ampli®ed with N-myc in neuroblastoma
To investigate the frequency of ampli®cation of NAG in neuroblastoma, we performed Southern blot analysis. A total of ten neuroblastoma cell lines and were digested with BamHI. The ®lters were hybridized sequentially with a 0.8 kb fragment of the N-myc probe pNb-1 and with the cloned NotI/DpnII fragment NBA-2A as probe for NAG a total of 65 neuroblastoma tumor samples were analysed. The genomic fragment NBA-2A was used as probe. Figure 3 shows a representative Southern blot of the neuroblastoma cell lines analysed. Cell lines SKNSH and Sy5y, which is a sub-clone of SKNSH, lack ampli®cation of N-myc and also lack NAG ampli®cation. Eight neuroblastoma cell lines contained an ampli®ed N-myc gene. Five of these (IMR-32, STA-NB-3, STA-NB-4, STA-NB-8, and STA-NB-11) also exhibited NAG ampli®cation. The remaining three cell lines (KCNR, NGP-127, and STA-NB-9) lacked NAG ampli®cation. Thus, we found coampli®cation of NAG in 63% (5/8) of the N-myc ampli®ed neuroblastoma cell lines. Of the 65 neuroblastoma tumors analysed, 52 lacked ampli®cation of N-myc and also did not amplify NAG. However, nine of 13 (70%) of the N-myc ampli®ed neuroblastomas exhibited ampli®cation of NAG (Figure 4) .
Ampli®cation of NAG correlates with over-expression in neuroblastoma cell lines
To examine whether NAG ampli®cation correlates with over-expression, we performed Northern blot analysis. Total RNA was prepared from ®ve neuroblastoma cell lines. Three of the cell lines (STA-NB-8, IMR-32, and KCNR), were ampli®ed for N-myc, the remaining two (SKNSH and Sy5y) had no Southerndetectable ampli®cation of N-myc. Two of the N-myc ampli®ed cell lines (STA-NB-8 and IMR-32) also contained an ampli®ed NAG gene (Figure 3) . Hybridization with the fetal heart c-DNA probe containing parts of the NAG gene clearly showed that ampli®cation of this fragment in the neuroblastoma cell lines STA-NB-8 and IMR-32 correlated with strong hybridization signals on the Northern ®lters ( Figure 5) .
To examine the expression pattern of NAG in normal tissues, a human master dot-blot containing poly-A + RNA dots of 50 dierent human tissues was hybridized with the fetal heart c-DNA probe. Hybridization signals were seen in all tissues but not in 100 ng human C o t1-DNA, suggesting that the signals were unique for NAG and not caused by cross-hybridization of the probe with repetitive sequences. The strongest hybridization signals were observed with fetal heart, kidney, liver, and lung, and the adult tissues testis, pancreas, pituitary, and adrenal (data not shown).
Discussion
We have identi®ed and cloned a genomic fragment containing a CpG island that is co-ampli®ed with the N-myc gene in neuroblastoma cell lines and tumors. The gene partly encoded by this fragment was cloned and characterized. The cloned c-DNA of NAG (Accession #AF056195) consists of 4510 nucleotides, which is consistent with Northern analysis detecting a message of approximately 4.5 kb. Translation of NAG predicts a 1352 amino acid protein. An EST database search and hybridization of a commercially available human dot-blot ®lter revealed the presence of NAG transcripts in a series of human tissues, including adult and fetal tissues, as well as tumor tissues, suggesting a wide range of expression. Two regions within the predicted NAG protein sequence exhibited signi®cant homology with two regions in a C. elegans protein of unknown function. The sequence similarity suggests that NAG contains conserved protein domains. Although no homology with other known genes in the database was found, highly signi®cant homology with mouse transcripts in the EST database implies that this protein also occurs in other mammals. Although, the function of NAG is as yet to be determined, its wide spectrum of expression and the occurrence of conserved sequences in its predicted protein suggests that it may serve an essential function.
The NAG gene that we mapped in close vicinity to N-myc on chromosome band 2p24 was found to be coampli®ed with N-myc. Ampli®cation of the N-myc oncogene is a well established prognostic factor in neuroblastoma, and it is known from transfection studies that over-expression of N-myc can contribute to cell transformation (Schwab et al., 1985) , and targeted expression of N-myc results in neuroblastoma in transgenic mice (Weiss et al., 1997) . Thus, N-myc is considered the main factor in driving the selective pressure for ampli®cation. However, a number of investigators have found that rearrangements are common in the neuroblastoma amplicon (Akiyama and Nishi, 1991; Amler and Schwab, 1992; Shiloh et al., 1986) , suggesting that there may be additional selective pressure for the inclusion or exclusion of other genes. It is also noteworthy that some studies have shown that not all tumors with N-myc ampli®cation are associated with a bad prognosis; for example, 50% of stage II tumors with N-myc ampli®cation have a good outcome De Bernardi et al., 1995) . Moreover, it has been demonstrated that increased N-myc expression seen in tumors that lack N-myc ampli®cation does not correlate with aggressive clinical behavior (Nisen et al., 1988; Slavc et al., 1990) . This ®nding and the fact that the N-myc amplicon usually contains sequences extending much further than the N-myc gene suggests that other genes present were ampli®ed for N-myc and two of these (STA-NB-8 and IMR-32) were also ampli®ed for NAG as determined by Southern blot (Figure 3) . The two remaining cell lines (SKNSH and Sy5y) had no Southern-detectable ampli®cation of N-myc and NAG. The ®lter was sequentially hybridized with a 0.8 kb fragment of the Nmyc probe pNB-1 and with the EST clone, that encompassed parts of the NAG gene in the N-myc amplicon which are over-expressed may in¯uence outcome in neuroblastoma. The DEAD-box gene DDX1 is another gene frequently co-ampli®ed with N-myc (George et al., 1996; Manohar et al., 1995; Squire et al., 1995) . NAG is co-ampli®ed with N-myc in 70% of the tumors we have analysed, which is approximately the same frequency of co-ampli®cation as for DDX1 (Manohar et al., 1995) . DDX1 has been mapped to a position at a maximum distance of 450 kb 5' to N-myc (Amler et al., 1996) , and FISH analysis on metaphases and extended free chromatin ®bers revealed that DDX1 is located telomeric to N-myc (Pandita et al., 1997) . Our two-color FISH analysis with N-myc and NAG also indicates a terminal location of NAG relative to N-myc. In addition, NAG and DDX1 show approximately the same frequency of co-ampli®cation with N-myc; thus, it is likely that both are located telomeric to N-myc. Akiyama et al. (1994) have shown that within a 500 kb region¯anking N-myc two NotI restriction sites are located less then 50 kb from each other. DDX1 has been mapped within this region, which is frequently co-ampli®ed with N-myc (Akiyama et al., 1994) . It is possible that the CpG island associated with NAG contains one of these two NotI sites.
In addition to fragments NBA-2A and NBA-2B that contained parts of the CpG island associated with NAG, three other fragments were also found at increased intensity in neuroblastoma cell lines that contained N-myc ampli®cation. These fragments have not been identi®ed. However, it is likely that they also represent genomic fragments containing CpG islands that are co-ampli®ed with N-myc. They are not derived from N-myc, since N-myc yields NotI/EcoRV fragments outside the ®rst-dimension separation range. Although there are no promoter sequences for the DDX1 gene in genomic databases, it is possible that one or two of the fragments are derived from an as yet uncloned CpG island associated with DDX1. Another gene that has been found to be rarely coampli®ed with N-myc is ODC-1 (Tonin et al., 1989) . The NotI/DpnII fragments predicted from the known sequence of a CpG island associated with ODC-1 do not correspond in size to the fragments that we have observed. Thus, the three additional NBA fragments would represent at least one additional CpG island that is associated with an ampli®ed gene in neuroblastoma. Therefore, full cloning of all NBAfragments observed in the neuroblastoma cell lines, as it is anticipated, will provide a clearer picture of which genes are frequently ampli®ed in neuroblastoma, as well as of the extent of heterogeneity of the N-myc amplicon.
Material and methods

Cell culture
Human neuroblastoma cell lines SKNSH (Biedler et al., 1973) , IMR-32 (Tumilowicz et al., 1970) , KCNR (Reynolds et al., 1986) , and NGP127 (Amler et al., 1995) have been characterized earlier. All STA-NB-3, -4, -8, -9, -11 cell lines (Ambros et al., 1997) have been established at the Children's Cancer Research Institute (Vienna, Austria) and showed the same karyotypic pattern as the tumors from which they were derived. All cell lines were maintained in RPMI containing 10% FBS.
DNA preparation for Southern blot and 2-D gel analysis
Genomic DNA was prepared from tumor tissue, peripheral blood lymphocytes, and cell lines. High molecular weight DNA was extracted from nuclei of *2610 7 cells. After phenol extraction of the proteinase K digest, the DNA was precipitated with ethanol and dissolved in 10 mM Tris plus 1 mM EDTA, pH 8.0 (TE buer).
2-D gel analysis
A detailed description of the experimental conditions can be found in (Asakawa et al., 1994; Hatada et al., 1991) . Brie¯y, genomic DNA was digested with NotI and EcoRV restriction enzymes, and the NotI derived 5' protruding ends were 32 P-labeled. After ®rst-dimensional separation of the fragments in agarose disc gels, a second digestion was done in situ with DpnII. The resulting fragments were separated perpendicularly in a polyacrylamide gel. 2-D gels were dried and exposed to PhosphoImager plates (Molecular Dynamics, Sunnyvale, CA, USA). Digital images were obtained after scanning of the PhosphoImager plates.
Cloning of the ampli®ed DNA fragments DNA fragments were cloned from preparative gels as previously described (Thoraval et al., 1996a) . Brie¯y, both radiolabeled and nonradiolabeled genomic digests of cell line STA-NB-11 were loaded onto ®rst-dimension agarose gels. After the second-dimension separation in polyacrylamide, the gels were exposed to X-ray ®lm (RX, Fuji) for 24 h at 7808C. The NotI/DpnII fragments corresponding to the DNA spots of interest were recovered and puri®ed by electrophoresis onto DEAE-cellulose membrane (Dretzen et al., 1981; Girvitz et al., 1980) . After electrophoresis, the DNA was recovered by elution with a high salt elution buer (50 mM Tris-HCl, pH 8.0, 1 M NaCl, 10 mM EDTA). After phenol-extraction and precipitation, the DNA was ligated in a NotI/BamHI digested pBC-vector (Clontech) in the presence of DNA ligase at 168C for 40 h. The transformation was performed by electroporation with the Epicurian Coli XL1-Blue MRF electroporationcompetent cells (Stratagene, La Jolla, CA, USA). After selection of the clones containing the insert, automated sequencing was performed at the University of Michigan Core Facility. For database comparison, the software programs Fasta from GCG package (Genetic Computer Group, WI, USA) and blastn and blastp (Altschul et al., 1990) were used.
A NotI/EcoRV fragment encompassing the NotI/DpnII fragment NBA-2A was isolated from a NotI/EcoRV whole genomic library that was created in a SK + pBluescript vector. The library was screened using the NotI/DpnII fragment NBA-2A as probe.
Southern, Northern and dot blot analysis
Genomic DNA of neuroblastoma cell lines and tumors was digested to completion with NotI/EcoRV or BamHI, respectively, and was electrophoresed in an agarose gel. Southern blot analysis was performed according to standard procedures (Church and Gilbert, 1984) , using a cloned NotI/DpnII fragment (NBA-2A) and a 0.8 PstI fragment of the N-myc probe pNB-1 (kindly provided by M Schwab). Bands were visualized by autoradiography. Total RNA was extracted from 5 neuroblastoma cell lines using TriZol-reagent (Gibco-BRL) and 4 mg were electrophoresed in a 6% formaldehyde gel in MOPS buer. The RNA was transferred onto Hybond N membrane (Amersham, Arlington Heights, IL, USA). Hybridization was performed in 50% formamide according to standard procedures. A human RNA master blot (ClonTech #7701) was hybridized using ExpressHyb TM solution (ClonTech) according to the manufacturer's instructions.
In situ Hybridization
Fluorescence in situ hybridization (FISH) on DAPI banded metaphase chromosomes (Schweizer and Ambros, 1994) from two normal, healthy donors (male and female) was performed by a modi®cation of the protocols of (Lichter et al., 1990) . Cells were harvested and slides prepared according to standard cytogenetic techniques. For double-color FISH, the metaphase chromosomes were hybridized with the biotinilated NotI/EcoRV fragment of NBA-2A simultaneously with the digoxygenin-labeled Nmyc probe. Twenty-one metaphase spreads were selected, and the images were analysed and stored using the ISIS software (MetaSystems, Altlussheim, Germany).
